Fibromyalgia & musculoskeletal pain
Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
Authors' conclusion
This is the first randomised controlled study demonstrating the effectiveness of the adding on therapy of PEA+ALC to DLX+PGB in FM patients.
Study context
- Population
- Fibromyalgia (FM) patients after three months of stable treatment with duloxetine (DLX)+pregabalin (PGB)130 (91.5%) completed
- Participants
- 142 patients
- Comparison
- Palmitoylethanolamide (PEA) + acetyl-L-carnitine (ALC) added to ongoing DLX+PGB vs continued DLX+PGB
- Group 2n = 62
- Group 1n = 68reference
- Primary endpoint
- WPI, time-integrated AUC
- Follow-up
- 24 weeks after randomisation
Methodological detailsadd-on
- Add-on
Primary result
As reported in the abstract
- Group 2 vs Group 1: P = 0.048
- Trial primary endpoint: Cumulative disease severity by Widespread Pain Index (WPI), assessed every two weeks, expressed as time-integrated AUC, Twenty-four weeks after randomisation
Secondary outcomes
| Outcome | P value |
|---|---|
| FIQR, time-integrated AUC · 24 weeks after randomisationBetter outcomes in Group 2 | P = 0.033 |
| FASmod, time-integrated AUC · 24 weeks after randomisationBetter outcomes in Group 2 | P = 0.017 |
Original publication
Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study. Clin Exp Rheumatol. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →